117 related articles for article (PubMed ID: 27402817)
1. Switching Lopinavir/Ritonavir to Atazanavir/Ritonavir vs Adding Atorvastatin in HIV-Infected Patients Receiving Second-Line Antiretroviral Therapy With Hypercholesterolemia: A Randomized Controlled Trial.
Wangpatharawanit P; Sungkanuparph S
Clin Infect Dis; 2016 Sep; 63(6):818-20. PubMed ID: 27402817
[TBL] [Abstract][Full Text] [Related]
2. Impact of switching from lopinavir/ritonavir to boosted and un-boosted atazanavir on glucose metabolism: the ATAzanavir & GLUcose metabolism (ATAGLU) study.
d'Ettorre G; Ceccarelli G; Zaccarelli M; Ascoli-Bartoli T; Bianchi L; Bellelli V; De Girolamo G; Serafino S; Giustini N; Mastroianni CM; Vullo V
Int J STD AIDS; 2016 Jul; 27(8):638-43. PubMed ID: 26068963
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of adhesion molecules and immune parameters in HIV-infected patients treated with an atazanavir/ritonavir- compared with a lopinavir/ritonavir-based regimen.
Squillace N; Trabattoni D; Muscatello A; Sabbatini F; Maloberti A; Giannattasio C; Masetti M; Fenizia C; Soria A; Clerici M; Gori A; Bandera A
J Antimicrob Chemother; 2018 Aug; 73(8):2162-2170. PubMed ID: 29897513
[TBL] [Abstract][Full Text] [Related]
4. An observational study in an urban Ugandan clinic comparing virological outcomes of patients switched from first-line antiretroviral regimens to second-line regimens containing ritonavir-boosted atazanavir or ritonavir-boosted lopinavir.
Laker EAO; Nabaggala MS; Kaimal A; Nalwanga D; Castelnuovo B; Musubire A; Kiragga A; Lamorde M; Ratanshi RP
BMC Infect Dis; 2019 Mar; 19(1):280. PubMed ID: 30909871
[TBL] [Abstract][Full Text] [Related]
5. [Insulin resistance in HIV-infected patients receiving long-term therapy with efavirenz, lopinavir/ritonavir and atazanavir].
Bernal E; Masiá M; Padilla S; Ramos JM; Martín-Hidalgo A; Gutiérrez F
Med Clin (Barc); 2007 Jul; 129(7):252-4. PubMed ID: 17683706
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of replacing lopinavir with atazanavir in HIV-infected patients with undetectable plasma viraemia: final results of the SLOAT trial.
Soriano V; García-Gasco P; Vispo E; Ruiz-Sancho A; Blanco F; Martín-Carbonero L; Rodríguez-Novoa S; Morello J; de Mendoza C; Rivas P; Barreiro P; González-Lahoz J
J Antimicrob Chemother; 2008 Jan; 61(1):200-5. PubMed ID: 17999977
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of atazanavir/ritonavir-based antiretroviral therapy for HIV-1 infected subjects: a systematic review and meta-analysis.
Menshawy A; Ismail A; Abushouk AI; Ahmed H; Menshawy E; Elmaraezy A; Gadelkarim M; Abdel-Maboud M; Attia A; Negida A
Arch Virol; 2017 Aug; 162(8):2181-2190. PubMed ID: 28361290
[TBL] [Abstract][Full Text] [Related]
8. Boosted lopinavir- versus boosted atazanavir-containing regimens and immunologic, virologic, and clinical outcomes: a prospective study of HIV-infected individuals in high-income countries.
; Cain LE; Phillips A; Olson A; Sabin C; Jose S; Justice A; Tate J; Logan R; Robins JM; Sterne JA; van Sighem A; Reiss P; Young J; Fehr J; Touloumi G; Paparizos V; Esteve A; Casabona J; Monge S; Moreno S; Seng R; Meyer L; Pérez-Hoyos S; Muga R; Dabis F; Vandenhende MA; Abgrall S; Costagliola D; Hernán MA
Clin Infect Dis; 2015 Apr; 60(8):1262-8. PubMed ID: 25567330
[TBL] [Abstract][Full Text] [Related]
9. Lipid-lowering efficacy and safety after switching to atazanavir-ritonavir-based highly active antiretroviral therapy in patients with human immunodeficiency virus.
Nguyen ST; Eaton SA; Bain AM; Rahman AP; Payne KD; Bedimo R; Herrington JD; Maclayton DO; Rodriguez-Barradas MC; Busti AJ
Pharmacotherapy; 2008 Mar; 28(3):323-30. PubMed ID: 18294112
[TBL] [Abstract][Full Text] [Related]
10. The lopinavir/ritonavir-associated rise in lipids is not related to lopinavir or ritonavir plasma concentration.
Bierman WF; van Vonderen MG; Veldkamp AI; Burger DM; Danner SA; Reiss P; van Agtmael MA
Antivir Ther; 2011; 16(5):647-55. PubMed ID: 21817186
[TBL] [Abstract][Full Text] [Related]
11. Effects of Pitavastatin on Lipid Profiles in HIV-Infected Patients with Dyslipidemia and Receiving Atazanavir/Ritonavir: A Randomized, Double-Blind, Crossover Study.
Wongprikorn A; Sukasem C; Puangpetch A; Numthavej P; Thakkinstian A; Kiertiburanakul S
PLoS One; 2016; 11(6):e0157531. PubMed ID: 27304841
[TBL] [Abstract][Full Text] [Related]
12. A cross-sectional study to evaluate second line virological failure and elevated bilirubin as a surrogate for adherence to atazanavir/ritonavir in two urban HIV clinics in Lilongwe, Malawi.
Ongubo DM; Lim R; Tweya H; Stanley CC; Tembo P; Broadhurst R; Gugsa S; Ngongondo M; Speight C; Heller T; Phiri S; Hosseinipour MC
BMC Infect Dis; 2017 Jul; 17(1):461. PubMed ID: 28673254
[TBL] [Abstract][Full Text] [Related]
13. Atazanavir / ritonavir versus Lopinavir / ritonavir-based combined antiretroviral therapy (cART) for HIV-1 infection: a systematic review and meta-analysis.
Tigabu BM; Agide FD; Mohraz M; Nikfar S
Afr Health Sci; 2020 Mar; 20(1):91-101. PubMed ID: 33402897
[TBL] [Abstract][Full Text] [Related]
14. Cost effectiveness of lopinavir/ritonavir compared with atazanavir in antiretroviral-naive patients: modelling the combined effects of HIV and heart disease.
Simpson KN; Luo MP; Chumney EC; King MS; Brun S
Clin Drug Investig; 2007; 27(1):67-74. PubMed ID: 17177581
[TBL] [Abstract][Full Text] [Related]
15. Lipid profiles in HIV-infected adults receiving atazanavir and atazanavir/ritonavir: systematic review and meta-analysis of randomized controlled trials.
Carey D; Amin J; Boyd M; Petoumenos K; Emery S
J Antimicrob Chemother; 2010 Sep; 65(9):1878-88. PubMed ID: 20554568
[TBL] [Abstract][Full Text] [Related]
16. Evolution of blood-associated HIV-1 DNA levels after 48 weeks of switching to atazanavir/ritonavir+lamivudine dual therapy versus continuing triple therapy in the randomized AtLaS-M trial.
Lombardi F; Belmonti S; Quiros-Roldan E; Latini A; Castagna A; D'Ettorre G; Gagliardini R; Fabbiani M; Cauda R; De Luca A; Di Giambenedetto S;
J Antimicrob Chemother; 2017 Jul; 72(7):2055-2059. PubMed ID: 28333353
[TBL] [Abstract][Full Text] [Related]
17. Lipid-lowering effect and efficacy after switching to etravirine in HIV-infected patients with intolerance to suppressive HAART.
Casado JL; de Los Santos I; Del Palacio M; García-Fraile L; Pérez-Elías MJ; Sanz J; Moreno S
HIV Clin Trials; 2013; 14(1):1-9. PubMed ID: 23372109
[TBL] [Abstract][Full Text] [Related]
18. Impact of protease inhibitors on the evolution of urinary markers: Subanalyses from an observational cross-sectional study.
Bonjoch A; Puig J; Pérez-Alvarez N; Juega J; Echeverría P; Clotet B; Romero R; Bonet J; Negredo E
Medicine (Baltimore); 2016 Aug; 95(32):e4507. PubMed ID: 27512868
[TBL] [Abstract][Full Text] [Related]
19. Post-exposure prophylaxis for HIV infection: a clinical trial comparing lopinavir/ritonavir versus atazanavir each with zidovudine/lamivudine.
Diaz-Brito V; León A; Knobel H; Peraire J; Domingo P; Clotet B; Dalmau D; Cruceta A; Arnaiz JA; Gatell JM; García F;
Antivir Ther; 2012; 17(2):337-46. PubMed ID: 22293542
[TBL] [Abstract][Full Text] [Related]
20. Rosuvastatin vs. protease inhibitor switching for hypercholesterolaemia: a randomized trial.
Lee FJ; Monteiro P; Baker D; Bloch M; Roth N; Finlayson R; Moore R; Hoy J; Martinez E; Carr A
HIV Med; 2016 Sep; 17(8):605-14. PubMed ID: 26987376
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
